We’re Not Very Worried About Xuanzhu Biopharmaceutical’s (HKG:2575) Cash Burn Rate

There’s no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.

So should Xuanzhu Biopharmaceutical (HKG:2575) shareholders be worried about its cash burn? For the purpose of this article, we’ll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). The first step is to compare its cash burn with its cash reserves, to give us its ‘cash runway’.

We’ve found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Does Xuanzhu Biopharmaceutical Have A Long Cash Runway?

You can calculate a company’s cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. When Xuanzhu Biopharmaceutical last reported its December 2025 balance sheet in April 2026, it had zero debt and cash worth CN¥652m. In the last year, its cash burn was CN¥250m. So it had a cash runway of about 2.6 years from December 2025. Arguably, that’s a prudent and sensible length of runway to have. You can see how its cash balance has changed over time in the image below.

See our latest analysis for Xuanzhu Biopharmaceutical

How Well Is Xuanzhu Biopharmaceutical Growing?

Some investors might find it troubling that Xuanzhu Biopharmaceutical is actually increasing its cash burn, which is up 25% in the last year. But looking on the bright side, its revenue gained by 72%, lending some credence to the growth narrative. The company needs to keep up that growth, if it is to really please shareholders. We think it is growing rather well, upon reflection. In reality, this article only makes a short study of the company’s growth data. You can take a look at how Xuanzhu Biopharmaceutical is growing revenue over time by checking this visualization of past revenue growth.

Can Xuanzhu Biopharmaceutical Raise More Cash Easily?

We are certainly impressed with the progress Xuanzhu Biopharmaceutical has made over the last year, but it is also worth considering how costly it would be if it wanted to raise more cash to fund faster growth. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Many companies end up issuing new shares to fund future growth. We can compare a company’s cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year’s operations.

Xuanzhu Biopharmaceutical’s cash burn of CN¥250m is about 5.0% of its CN¥5.0b market capitalisation. Given that is a rather small percentage, it would probably be really easy for the company to fund another year’s growth by issuing some new shares to investors, or even by taking out a loan.

Is Xuanzhu Biopharmaceutical’s Cash Burn A Worry?

It may already be apparent to you that we’re relatively comfortable with the way Xuanzhu Biopharmaceutical is burning through its cash. In particular, we think its revenue growth stands out as evidence that the company is well on top of its spending. Although its increasing cash burn does give us reason for pause, the other metrics we discussed in this article form a positive picture overall. Looking at all the measures in this article, together, we’re not worried about its rate of cash burn; the company seems well on top of its medium-term spending needs. Readers need to have a sound understanding of business risks before investing in a stock, and we’ve spotted 1 warning sign for Xuanzhu Biopharmaceutical that potential shareholders should take into account before putting money into a stock.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies with significant insider holdings, and this list of stocks growth stocks (according to analyst forecasts)

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.